Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis

There is a need to synthesise the results of numerous randomised controlled trials evaluating the addition of therapies to androgen deprivation therapy (ADT) for men with metastatic hormone-sensitive prostate cancer (mHSPC). This systematic review aims to assess the effects of adding abiraterone ace...

Full description

Saved in:

Bibliographic Details
Published in:	European journal of cancer (1990) Vol. 84; pp. 88 - 101
Main Authors:	Rydzewska, Larysa H.M., Burdett, Sarah, Vale, Claire L., Clarke, Noel W., Fizazi, Karim, Kheoh, Thian, Mason, Malcolm D., Miladinovic, Branko, James, Nicholas D., Parmar, Mahesh K.B., Spears, Melissa R., Sweeney, Christopher J., Sydes, Matthew R., Tran, NamPhuong, Tierney, Jayne F.
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 01.10.2017 Elsevier Science Ltd
Subjects:	Abiraterone Acetic acid Acute toxicity Age Factors Aged Androgen Antagonists - adverse effects Androgen Antagonists - therapeutic use Androgen deprivation therapy Androstenes - adverse effects Androstenes - therapeutic use Antineoplastic Agents, Hormonal - adverse effects Antineoplastic Agents, Hormonal - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer Chi-Square Distribution Clinical trials Clinical Trials as Topic Confidence intervals Deprivation Disease-Free Survival Endocrine therapy Endocrinology Heart diseases Humans Lymphatic Metastasis Male Men Meta-analysis Metastases Metastasis Middle Aged Neoplasm Grading Neoplasms, Hormone-Dependent - drug therapy Neoplasms, Hormone-Dependent - mortality Neoplasms, Hormone-Dependent - pathology Odds Ratio Prednisolone Prednisolone - therapeutic use Prednisone Prednisone - therapeutic use Prostate cancer Prostatic Neoplasms - drug therapy Prostatic Neoplasms - mortality Prostatic Neoplasms - pathology Randomization Reduction Risk Factors Subgroups Survival Systematic review Therapy Time Factors Toxicity Treatment Outcome Systematic review Androgen deprivation therapy Abiraterone Prostate cancer Metastases Meta-analysis
ISSN:	0959-8049, 1879-0852, 1879-0852
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!